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Abstract C14ORF166 (chromosome 14 open reading frame
166) is a transcriptional repressor related to the regulation of
centrosome architecture. However, the role of C14ORF166 in
the development and progression of cancer remains largely
unknown. The aim of this study was to investigate the expres-
sion and clinicopathological significance of C14ORF166 in
cervical cancer. C14ORF166 expression was analyzed using
quantitative real-time PCR (RT-PCR) and Western blotting in
cervical cancer cell lines and eight paired cervical cancer sam-
ples and the adjacent normal tissues. Immunohistochemistry
was used to analyze C14ORF166 protein expression in 148
clinicopathologically characterized cervical cancer specimens.
Statistical analyses were performed to evaluate the relation-
ship between the expression of C14ORF166 and clinicopath-
ologic features and prognosis. C14ORF166 mRNA and pro-
tein expression were significantly upregulated in cervical can-
cer cell lines and tissue samples (P<0.05). Immunohisto-
chemical analysis revealed a high expression of
C14ORF166 was observed in 39.9 % (59/148) of the cervical
cancer specimens; the remaining samples expressed low
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levels or did not express any detectable C14ORF166. The chi-
square test indicated that high-level expression of
C14ORF166 was significantly associated with International
Federation of Gynecology and Obstetrics (FIGO) stage
(P<0.001), vital status (P=0.026), tumor size (P=0.034), se-
rum squamous cell carcinoma antigen level (SCC-Ag; P=
0.035), and pelvic lymph node metastasis (P<0.001). Patients
with highly expressed C14ORF166 showed a tendency to
receive postoperative chemotherapy (P=0.005) and postoper-
ative radiation (P=0.008). Furthermore, high C14ORF166
expression was associated with poorer overall survival com-
pared to low C14ORF166 expression, and C14ORF166 was a
significant prognostic factor in univariate and multivariate
analysis (P<0.05). High C14ORF166 expression had prog-
nostic value for poor outcome in cervical cancer.
C14ORF166 may represent a biomarker of pelvic lymph node
metastasis and enable the identification of high-risk patients
along with selection of appropriate treatment strategies.
Keywords C14ORF166 . Cervical cancer . Lymph node
metastasis . Prognosis . Biomarker
Introduction
Cervical cancer is the third most common malignancy among
females worldwide, with an estimated global incidence of
more than 500,000 new cases and 260,000 deaths every year
[1]. Cervical cancer is prevalent in developing countries,
where it remains a major cause of mortality among females
[2]. Viral infection, genetic susceptibility, and environmental
factors are associated with the etiology of cervical cancer. The
development of cervical lesions from cervical intraepithelial
neoplasia (CIN) to cervical cancer is a complicated process
that is initiated by persistent infection with high-risk types of
human papillomavirus (HPV) [3]. Altered expression of a
variety of oncogenes and tumor suppressor genes has also
been associated with cervical cancer [4]. However, the precise
mechanisms that regulate the pathogenesis of cervical cancer
are poorly characterized, and a specific genetic signature to
predict prognosis has not yet been identified in cervical can-
cer. Conventional clinical, diagnostic, and pathological vari-
ables such as International Federation of Gynecology and Ob-
stetrics (FIGO) stage, tumor size, and the depth of infiltration
are still used extensively to predict prognosis but are not suf-
ficiently reliable to predict clinical outcome [5]. Patients with
lymph node metastasis have a higher rate of mortality than
patients without lymph node metastasis [6], and assessment
of lymph node metastasis provides important information for
determining the appropriate treatment approach [7]. Hence, it
would be of clinical significance to identify biomarkers of
lymph node metastasis or prognostic factors in patients with
cervical cancer.
C14ORF166 is located on chromosome 14 at 14q22.1 and
encodes a highly conserved 28-kDa protein.C14ORF166was
originally identified as an influenza A virus-associated gene
and may modulate transcription by interacting with various
transactivators [8]. C14ORF166 has been suggested to play
a prominent role in the fate of nuclear and cytoplasmic RNA.
The C14ORF166-DDX1-HSPC117-FAM98B complex is
present in both cellular compartments and transports RNA
molecules between the nucleus and the cytoplasm [9]. Inter-
estingly, overexpression of C14ORF166 has been observed in
a variety of human cancers. Wang et al. [10] reported that
C14ORF166 is highly expressed in a variety of brain tumors
and is differentially expressed during normal brain develop-
ment. Recently, C14ORF166 was reported to be a potential
biomarker for metastasis in patients with human pancreatic
carcinoma [11, 12]. Along with acylglycerol kinase (AGK),
C14ORF166 has been implicated in the JAK2/STAT3 signal-
ing pathway in esophageal squamous cells [13]. The JAK2/
STAT3 pathway has been reported to play a crucial role in
regulating the progression of cervical cancer [14, 15]. How-
ever, the protein expression level and role of C14ORF166 in
cervical cancer have not been investigated.
In the current study, we aimed to explore the expression of
C14ORF166 in cervical cell lines and human cervical tissues.
Moreover, we investigated the association between the ex-
pression of C14ORF166 protein and clinical significances




Patient consent was obtained prior to the use of the clinical
materials for research purposes, and the patient consent and
protocol were approved by Sun Yat-Sen University Cancer
Center Institutional Review Board. A primary culture of nor-
mal cervical epithelial cells was established from a biopsy of
noncancerous cervical epithelium and was cultured in com-
plete Keratinocyte-SFM medium (Invitrogen, Carlsbad, CA,
USA). The cervical cancer cell lines HeLa, SiHa, C33A,
MS751, CasKi, HeLa229, and HCC94 were cultured in
RPMI-1640 medium (GIBCO BRL), and ME-180 was cul-
tured in DMEMmedium (Gibco, Grand Island, NY, USA), all
supplemented with 10 % fetal bovine serum (HyClone Labo-
ratories, Logan, UT).
Patients and tissue samples
For real-time PCR (RT-PCR) and Western blot analysis, we
collected 8 paired cervical cancers and adjacent normal tissues
from the patients who underwent surgery between 2013 and
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2014. A total of 148 cases of paraffin-embedded cervical can-
cer samples had been clinically and histologically diagnosed
at the Sun Yat-Sen University Cancer Center (Guangzhou,
China) from 2001 to 2005. Clinical and clinicopathological
classification and staging of all the patients were defined ac-
cording to the International Federation of Gynecology and
Obstetrics (FIGO) criteria (Pecorelli, 2009): 51 were respec-
tively allocated to stage I; 80 to stage II; 15 to stage III; and 2
to stage IV. The patients’ age ranged from 25 to 68 years
(mean, 42.57 years). Clinicopathological characteristics of
the tumor cases are presented in Table 1. The follow-up time
of the cohort ranged from 2 to 132 months, with a median
follow-up time of 51.65 months.
Real-time PCR
Total RNA samples from cell lines and fresh surgical cervical
cancer tissue were isolated using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instruc-
tions. The extracted RNA was pretreated with RNase-free
DNase, and approximately 2 μg of RNA from each sample
was used for cDNA synthesis primed with random hexamers.
For the PCR amplification of C14ORF166 cDNA, an initial
amplification step using C14ORF166-specific primers was
performed with denaturation at 95 °C for 10 min. This was
followed by 28 denaturation cycles at 95 °C for 60 s, primer
annealing at 58 °C for 30 s, and a primer extension phase at
72 °C for 30 s. Upon the completion of the cycling steps, a
final extension step at 72 °C for 5 min was performed before
the reaction mixture was stored at 4 °C. Real-time PCR was
then employed to determine the increase of C14ORF166
mRNA in each of the primary cervical tumors relative to the
paired normal cervical tissue taken from the same patient. The
primers were designed using Primer Express v 2.0 software
(Applied Biosystems). The C14ORF166 sense primer was 5′-
TGCATTGTCAGCAGTTTTTGA-3′, and the antisense
primer was 5′-TGACTGGCTTCTTGGTTTAGC-3′. For the
G A D P H g e n e , t h e s e n s e p r i m e r w a s 5 ′ -
TTGAGGTCAATGAAGGGGTC-3′, and the antisense prim-
er was 5′-GAAGGTGAAGGTCGGAGTCA-3′. Expression
data were normalized to the geometric mean of the housekeep-
ing gene GADPH to control the variability in expression
levels and calculated as 2-[(Ct of C14ORF166)—(Ct of
GADPH)], where Ct represents the threshold cycle for each
transcript.
Western blotting
Sample preparation for immunoblotting was performed as
previously described. Cells at 80 to 90 % confluence were
washed twice with ice-cold phosphate-buffered saline (PBS)
and lysed on ice in radio immunoprecipitation assay buffer
(RIPA; Cell Signaling Technology, Danvers, MA) containing
complete protease inhibitor cocktail (Roche Applied Sciences,
Mannheim, Germany). Fresh tissue samples were ground to
powder in liquid nitrogen and lysed with SDS-PAGE sample
buffer. Protein concentration was determined by the Bradford
assay (Bio-Rad Laboratories, Hercules, CA). Equal amounts
of proteins (30 μg) were separated electrophoretically on
10.5 % SDS/polyacrylamide gels and transferred onto PVDF
Table 1 Clinicopathological characteristics and tumor expression of
C14ORF166 in patients with cervical cancer










Squamous carcinoma 143 (96.6)
Adenocarcinoma 5 (3.4)




Low or none 89 (60.1)
High 59 (39.9)
Tumor size, cm
<4 cm 71 (48.0)

















Squamous cell carcinoma antigen, ng/ml
≤1.5 93 (62.8)
>1.5 55 (37.2)
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membranes (Immobilon P, Millipore, Bedford, MA). Mem-
branes were blocked with 5 % fat-free milk in Tris-buffered
saline containing 0.1 % Tween-20 (TBS-T) for 1 h at room
temperature. Membranes were probed with an anti-
C14ORF166 rabbit polyclonal antibody (1:2000, Proteintech)
overnight at 4 °C. After washing with TBS-T, the membrane
was incubated with a secondary antibody against mouse im-
munoglobulin G. The membrane was washed, and protein
was detected by enhanced chemiluminescence (Amersham
Pharmacia Biotech) according to the manufacturer’s instruc-
tions. An anti-α-tubulin mouse monoclonal antibody (1:1000;
Santa Cruz Biotechnology, Santa Cruz, CA) was used to con-
firm equal loading.
Immunohistochemical analysis
Immunohistochemistry was done to examine C14ORF166
expression in 148 human cervical cancer specimens. Briefly,
paraffin-embedded tissues were cut into 4-Am sections and
baked at 60 °C for 1 h. The sections were deparaffinized with
xylenes, rehydrated, then submerged into citrate antigenic re-
trieval buffer and microwaved for antigenic retrieval. The
samples were then treated with 3 % hydrogen peroxide in
methanol to quench the endogenous peroxidase activity,
followed by incubation with 1 % bovine serum albumin to
block the nonspecific binding. Finally, the sections were incu-
bated with anti-C14ORF166 rabbit polyclonal antibody
(1:200, Proteintech) overnight at 4 °C. For negative controls,
the primary antibody was replaced by normal goat serum.
After washing, the tissue sections were then incubated with
the biotinylated antimouse secondary antibody (Abcam),
followed by further incubation with streptavidin-horseradish-
peroxidase complex (Abcam). The tissue sections were im-
mersed in 3-amino-9-ethyl carbazole, counterstained with
10 %Mayer’s hematoxylin, dehydrated, and mounted in crys-
tal mount.
The degree of immunostaining of formalin-fixed, paraffin-
embedded sections was reviewed and scored by three inde-
pendent observers who were blinded to the histopathological
features and patient data of the samples. The scores given by
the three independent investigators were averaged and based
on both the proportion of positively stained tumor cells and
the intensity of staining. The intensity of protein expression
was recorded as follows: 0 (no staining), 1 (weak staining,
light yellow), 2 (moderate staining, yellowish brown), and 3
(strong staining, brown). The proportion of tumor cells was
scored as follows: 1 (<10 % positive tumor cells), 2 (10–50 %
positive tumor cells), 3 (50–75 % positive tumor cells), and 4
(>75 % positive tumor cells). The staining intensity and the
proportion of positive cell scores for each section were multi-
plied (scored as 0, 1, 2, 3, 4, 6, 8, 9, or 12). Using this method
of assessment, we evaluated the expression of C14ORF166 in
cervical cancer tissue. Cut-off values for C14ORF166 were
chosen on the basis of a measure of heterogeneity using the
log-rank test with respect to overall survival (OS). An optimal
cut-off value was identified as follows: a staining index score
of >6 was utilized to define tumors with high C14ORF166
expression and ≤6 suggested low C14ORF166 expression. To
account for the inconsistencies in IHC stain intensities, the
mean optical density (MOD) method, which was used for
the scoring of the staining intensity, was applied in the current
study.
Statistical analysis
All statistical analyses were conducted using the SPSS 16.0
statistical software packages. In the real-time PCR and West-
ern blot analysis, the significance of mRNA and protein ex-
pression between cervical cancers and the adjacent normal
tissues was analyzed by t test. We analyzed the relationship
between expression of C14ORF166 protein, clinicopathologic
features, and the clinical prognosis. The chi-square test and
Fisher’s exact test were used to analyze the relationship be-
tween C14ORF166 expression and clinicopathological char-
acteristics. Bivariate correlations between study variables
were calculated by association analysis. Survival curves were
plotted by the Kaplan–Meier method and compared using the
log-rank test. Using the Cox proportional hazards regression
model in the univariate and multivariate analysis, the signifi-
cance of various variables which were mentioned above for
survival was analyzed to predict prognosis in clinical practice.
In all cases, a P value of less than 0.05 was considered to be
statistically significant.
Results
C14ORF166 is overexpressed in cervical cancer cell lines
RT-PCR and Western blotting were performed to determine
C14ORF166 mRNA and protein expression in eight cervical
cancer cell lines (HeLa, SiHa, C33A, MS751, CasKi,
HeLa229, HCC94, and ME-180) and normal cervical cell
lines (NC). As shown in Fig. 1a and b, both C14ORF166
mRNA and protein were expressed at high levels in all cervi-
cal cancer cell lines tested compared to normal cervical lines.
C14ORF166 is overexpressed in human cervical cancer
To evaluate the expression of C14ORF166 in human cervical
cancer, RT-PCR and Western blotting were performed on cer-
vical cancer specimens of eight patients and their paired adja-
cent noncancerous tissues. All eight human cervical cancer
tissue samples expressed high levels of C14ORF166 mRNA
and protein; whereas, C14ORF166 was expressed at low
levels in the adjacent normal tissues (Fig. 2a, b).
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C14ORF166 protein expression was assessed in 148
paraffin-embedded archived cervical cancer tissues by immu-
nohistochemical staining using an antibody against human
C14ORF166. Either no immunoreactivity or only weak stain-
ing was observed in the adjacent noncancerous tissues and
normal cervical tissues; whereas, C14ORF166 was expressed
at high levels in the cervical cancer tissues (Fig. 2c). In the
tumor tissues, C14ORF166 was primarily localized in the tu-
mor cell nuclei with strong cytoplasmic staining occasionally
observed (Fig. 3a). High levels of C14ORF166 protein ex-
pression were observed in 59/148 patients (39.9 %), and weak
or no staining was observed in 89 patients (60.1 %; Table 1).
Furthermore, the statistical analyses of the average mean op-
tical density (MOD) of C14ORF166 staining in normal cervi-
cal tissues and cervical cancer specimens at different clinical
stages revealed that C14ORF166 expression increased with
advancing FIGO stage in cervical cancer (Fig. 3).
C14ORF166 expression correlates
with the clinicopathologic features of cervical cancer
The correlation between expression of C14ORF166 protein
and the clinicopathological features of cervical cancer were
analyzed using the chi-square test and Fisher’s exact test
(Table 2). High expression of C14ORF166 protein was sig-
nificantly associated with FIGO stage (P<0.001), vital status
(P=0.026), tumor size (P=0.034), pelvic lymph node metas-
tasis (P<0.001), and serum squamous cell carcinoma antigen
level (P=0.035). Patients with highly expressed C14ORF166
showed a tendency to receive postoperative chemotherapy
(P=0.005) and postoperative radiation (P=0.008). However,
there were no statistically significant correlations between
C14ORF166 protein expression and other clinicopathologic
features such as patient age, histological differentiation, and
recurrence.
Association analysis was performed to confirm the corre-
lations between C14ORF166 expression and the clinicopath-
ological features of cervical cancer. As shown in Table 3, sta-
tistically significant correlations were observed between
C14ORF166 expression and FIGO stage (0.561; P<0.001),
pelvic lymph node metastasis (0.465; P<0.001), tumor size
(0.172; P=0.034), and the serum squamous cell carcinoma
antigen level (0.171; P=0.035). In addition, patients with
highly expressed C14ORF166 showed a tendency to receive
postoperative chemotherapy (0.224; P=0.005) and postoper-
ative radiation (0.213; P=0.008).
Increased C14ORF166 expression is associated with poor
prognosis in cervical cancer
Kaplan–Meier survival analysis and the log-rank test indicat-
ed that a high level of C14ORF166 protein expression was
associated with significantly poorer 5-year overall survival
(OS, P<0.001; Fig. 4a) and 5-year disease-free survival
(DFS, P<0.001; Fig. 4b) in patients with cervical cancer.
We observed that the cumulative 5-year overall survival rate
was 87 % (95 % CI, 86.9~87.1 %) in the low C14ORF166
group; whereas, it was only 65 % (95 % CI, 67.6~68.0 %) in
the high C14ORF166 group.
In subgroup analysis, high-level expression of
C14ORF166 was associated with significantly poorer OS in
patients without pelvic lymph node metastasis (P=0.041;
Fig. 4c) and patients with stages I and II disease (P=0.027;
Fig. 4d) but not in patients with stages III and IV disease (P=
0.414; data not shown); the lack of a statistically significant
association may be due to the limited number of patients in
each subset.
Moreover, univariate Cox regression and multivariate sur-
vival analysis indicated that C14ORF166 expression (P=
0.036), FIGO stage (P=0.009), recurrence (P=0.003), and
pelvic lymph node metastasis (P=0.013) were independent
prognostic factors for poor overall survival (Table 4). There-
fore, these findings indicate that C14ORF166 may represent a
valuable prognostic marker in cervical cancer.
Discussion
In this study, we provide the first evidence that increased ex-
pression of C14ORF166 is a common feature and may repre-
sent a potential prognostic marker in cervical cancer.
Fig. 1 Overexpression of C14ORF166 mRNA and protein in cervical
cancer cell lines. a, b Expression of C14ORF166 mRNA and protein in
cervical cancer cell lines (HCC94, HeLa229, C33A, HeLa, ME-180,
SiHa, MS751, CasKi) and normal cervical cell lines were examined by
Western blotting (a) and qPCR (b). Expression levels were normalized
against GAPDH respectively. Error bars represent the standard deviation
of the mean (SD) calculated from three parallel experiments. *p<0.05
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Interestingly, C14ORF166 protein expression was also signif-
icantly associated with pelvic lymph node metastasis, clinical
stage, vital status, tumor size, and serum squamous cell carci-
noma antigen level.
In the present study, overexpression of C14ORF166 was
not only observed in HPV-positive cervical cancer cell lines,
such as HeLa, SiHa, and CasKi, but also in the HPV-negative
cervical cancer cell line C33A. Moreover, immunohistochem-
ical analysis revealed that C14ORF166 was overexpressed in
the majority of human cervical cancer tissue specimens tested,
in agreement with previous studies in brain cancer [10] and
pancreatic cancer [11, 12]. However, the molecular mecha-
nisms responsible for overexpression of C14ORF166 in can-
cer remain largely unknown.
A number of potential biomarkers, including tissue
polypeptide antigen (TPA) and tissue polypeptide-
specific antigen (TPS) have been suggested to have prog-
nostic value in cervical cancer; however, the data
concerning these antigens is conflicting and further stud-
ies are required [16–18]. In this cohort, we showed that
aberrant expression of C14ORF166 protein was associat-
ed with significantly poorer 5-year OS and DFS. Multi-
variate Cox regression analysis revealed that a high level
of C14ORF166 was an independent prognostic marker
for cervical cancer. Taken together, our study indicated
that C14ORF166 could be a novel prognostic biomarker
to identify cervical cancer patients with poor clinical
outcome.
In this study, high expression of C14ORF166 protein cor-
related significantly with advanced tumor stage, larger tumor
size, death, lymph node metastasis, and poorer survival, sug-
gesting that C14ORF166 may not only play a role in promot-
ing the growth of the primary tumor but may also be associ-
ated with the development of lymph node metastasis in cervi-
cal cancer. Associations between C14ORF166 protein expres-
sion and the clinical features of other types of cancer have
been reported. Guo et al. [11] and Cur et al. [12] showed that
expression of C14ORF166 was significantly associated with
an aggressive phenotype in pancreatic carcinoma, and Wang
et al. [10] reported that expression of C14ORF166 was
Fig. 2 Overexpression of
C14ORF166 mRNA and protein
in cervical cancer tissues. a
Representative images of Western
blotting analyses of C14ORF166
protein expression in eight
matched pairs of cervical cancer
(T) and adjacent noncancerous
tissues. The expression level was
normalized by α-tubulin
expression. b Average T/N ratios
of C14ORF166 mRNA
expression in paired cervical
cancer (T) and adjacent
noncancerous tissues (N) were
quantified by qPCR and
normalized against GAPDH.
Error bars represent the standard
deviation of the mean (SD)




in eight pairs of matched cervical
cancer tissues. *p<0.05
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associated with poor prognostic factors in brain cancer. This
evidence indicates that C14ORF166 may play a role in the
pathogenesis of various types of cancer.
Recently, Chen et al. [13] investigated the JAK2/STAT3
pathway in esophageal cancer using immunoprecipitation as-
says and demonstrated C14ORF166 was a binding partner of
JAK2. JAK2, a member of the Janus (JAK) family of
nonreceptor protein tyrosine kinases, functions as a prototyp-
ical kinase to mediate the phosphorylation of signal transducer
and activator of transcription 3 (STAT3), thus regulating the
JAK2/STAT3 signaling pathway [19, 20]. Activation of the
JAK2/STAT3 pathway is associated with inflammation, and
inflammation subsequent to viral infection is one factor that
initiates and promotes the development of cancer [21–25].
Hyperactivation of inflammatory pathways plays an important
role in cervical cancer tumorgenesis, and promotes progres-
sion from low-grade lesions to invasive cervical cancer [26].
Additionally, Sobti et al. [27] indicated a potentially interac-
tive effect between HPV16/18 and activation of the JAK2/
STAT3 pathway in cervical carcinogenesis. Furthermore, it
was reported that the JAK2/STAT3 pathway regulates cervical
cancer progression [14, 15]. These studies indicate that
overexpression of C14ORF166 may affect the development
and progression of cervical cancer by modulating the JAK2/
STAT3 signaling pathways; further characterization of these
processes may provide new insight and novel targets for the
treatment of cervical cancer. The molecular mechanism that
links C14ORF166 to tumor progression in cervical cancer
remains to be elucidated, and further studies are warranted.
It is widely recognized that various treatment strategies
lead to different clinical outcomes in patients with cervical
cancer. Currently, assessment of lymph node metastasis pro-
vides important information for determining the appropriate
treatment approach, such as surgical resection and chemora-
diation [28, 29]. Moreover, lymph node metastasis is an im-
portant cause of cervical cancer-related mortality [30].
Noordhuis et al. [31] found that patients with early-stage cer-
vical cancer who did not have lymph node metastasis had a 5-
year overall survival rate of 90 % compared to only 65 % for
patients with lymph node metastasis. However, there are no
accurate and efficient techniques for diagnosing pelvic lymph
node metastasis to help gynecologic oncologists select the
appropriate treatment and avoid unnecessary surgical inter-
vention [32]. Interestingly, we observed that C14ORF166
Fig. 3 a The expression of
C14ORF166 protein in cervical
cancer tissues from patients at
different clinical stages. b The
average MOD of C14ORF166
staining between the normal
cervical tissues (four cases) and
different clinical stage cervical
tissues (randomly picked 10 cases
per stage) were statistically
quantified. The average MOD of
C14ORF166 staining increases as
cervical cancer progresses to
more advanced stages (P<0.001).
Error bars represent mean±SD
from three independent
experiments.
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was significantly associated with pelvic lymph node metasta-
sis (P<0.001). In accordance with these results, Guo et al. [11]
and Cui et al. [12] previously reported that C14ORF166 was a
novel lymph node metastasis-associated protein in pancreatic
cancer. Hence, we suggest that C14ORF166 has potential as a
novel predictor of pelvic lymph node metastasis; additional
multi-center prospective studies are required to validate this hy-
pothesis. Additionally, further study of the role of C14ORF166
in invasion and metastasis may help to clarify the mechanisms
that regulate metastasis and identify novel therapeutic targets for
cervical cancer.
Squamous cell carcinoma antigen (SCC-Ag) is commonly
employed in the clinic for cervical cancer screening and as an
important prognostic factor for patient survival [33]. High
serum SCC-Ag levels have been associated with pelvic lymph
node metastasis, tumor stage, tumor size, recurrence, and
Table 2 Correlation between C14ORF166 expression and the clinicopathologic features of cervical cancer








Age (years) <50 114 67 (45.3) 47 (31.8) 0.535 0.557
≥50 34 22 (14.9) 12 (8.1)
FIGO stage I 51 46 (31.1) 5 (3.4) <0.001 –
II 80 42 (28.4) 38 (25.7)
III 15 1 (0.7) 14 (9.4)
IV 2 0 (0) 2 (1.4)
Pelvic lymph node metastasis Absent 115 85 (57.4) 30 (20.3) <0.001 <0.001
Present 33 4 (2.7) 29 (19.6)
Tumor size <4 cm 71 49 (33.1) 22 (14.9) 0.034 0.044
≥4 cm 77 40 (27.0) 37 (25.0)
Tumor recurrence No 133 81 (54.0) 52 (36.5) 0.570 0.588
Yes 15 8 (5.4) 7 (4.1)
Vital status (at last follow-up) Alive 127 81 (54.7) 46 (31.1) 0.026 0.032
Dead 21 8 (5.4) 13 (8.8)
Differentiation G1 3 2 (1.4) 1 (0.7) 0.952 –
G2 59 36 (24.3) 23 (15.5)
G3 86 51 (34.5) 35 (23.6)
Postoperative chemotherapy No 47 36 (24.3) 11 (7.4) 0.005 0.007
Yes 101 53 (35.8) 48 (32.4)
Postoperative radiation No 92 63 (42.6) 29 (19.6) 0.008 0.010
Yes 56 26 (17.5) 30 (20.3)
Squamous cell carcinoma antigen, ng/ml ≤1.5 93 62 (41.9) 31 (21.0) 0.035 0.039
>1.5 55 27 (18.2) 28 (18.9)
Table 3 Correlation between
C14ORF166 expression and the
clinicopathological characteristics
of patients with cervical cancer
Variable C14ORF166 expression
Association coefficient P value
Age 0.051 0.535
FIGO Stage 0.561 <0.001
Pelvic lymph node metastasis 0.465 <0.001
Tumor size 0.172 0.034
Recurrence 0.047 0.570
Vital status 0.180 0.026
Differentiation grade 0.026 0.952
Postoperative chemotherapy 0.224 0.005
Postoperative radiation 0.213 0.008
Squamous cell carcinoma antigen, ng/ml 0.171 0.035
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survival in cervical cancer [34–36]. However, SCC-Ag is nei-
ther cervix-specific nor malignancy-specific; the serum levels
of SCC-Ag are significantly elevated in patients with lung
cancer, esophageal squamous cell carcinoma, and head and
neck squamous cell carcinoma [37–39]. Torre et al. [40] also
indicated that serum SCC-Ag was elevated in patients with




(log-rank test). a, b OS (a) and 5-
year DFS (b) rates for cases with
high C14ORF166 expression
versus those for cases with low
C14ORF166 expression levels in
all patients. c, d OS rate for
without lymph node metastasis
cases (c) and clinical stage I/II
cases (d) with high C14ORF166
expression versus those for cases
with low C14ORF166 expression
levels.
Table 4 Univariate and multivariate analyses of prognostic factors in cervical cancer using a Cox regression model
Univariate analysis Multivariate analysis
No. of patients P Regression coefficient (SE) P Relative risk 95 % confidence interval
Pelvic lymph node metastasis








Low expression 89 <0.001 2.104 (0.503) 0.036 4.017 1.095–14.731
High expression 59
Recurrence 0.004 1.396 (0.485) 0.003 4.419 1.659–11.768
No 133
Yes 15
Tumor Biol. (2016) 37:369–379 377
benign conditions including tuberculosis, eczema, and pem-
phigus. Kim et al. [41] demonstrated that increased serum
SCC-Ag (>2.0 ng/mL) may be predictive for lymph node
metastases in early-stage cervical carcinoma, and Takeda
et al. [42] reported that serum SCC-Ag levels over 1.5 ng/ml
were significantly associated with lymph node metastasis.
However, the cutoff levels for SCC-Ag varied from study to
study resulting in vastly different sensitivity and specificity
values for this marker [34, 43, 44], and a normal pretreatment
SCC-Ag level does exclude the presence of lymph node me-
tastases in cervical cancer [45]. Therefore, the predictive value
of serum SCC-Ag for pelvic lymph node metastases in cervi-
cal carcinoma is unsatisfactory [17]. Herein, we found that
C14ORF166 was strongly associated with and may therefore
represent a valuable biomarker of pelvic lymph node metas-
tasis. Thus, C14ORF166 may be useful for evaluating prog-
nosis and guiding follow-up therapy in cervical cancer. Addi-
tionally, C14ORF166 can be detected in the serum of patients
with pancreatic cancer [9]; however, we did not explore the
expression of C14ORF166 in the serum of patients with cer-
vical cancer. Therefore, further investigation is required to
confirm whether C14ORF166 has potential as predictive bio-
marker for identifying patients with pelvic lymph node
metastasis.
Conclusion
In our study, we report that the expression of C14ORF166
is upregulated in cervical cancer cells and human surgical
specimens. Additionally, C14ORF166 was significantly as-
sociated with pelvic lymph node metastasis, clinical stage,
tumor size, vital status, and the serum squamous cell car-
cinoma antigen level. Patients with highly expressed
C14ORF166 showed a tendency to receive postoperative
chemotherapy and postoperative radiation. Multivariate
analysis revealed that C14ORF166 was an independent
prognostic factor for cervical cancer. Taken together, these
results suggest that C14ORF166 may play an important
role in the development and progression of human cervical
carcinoma. C14ORF166 may represent a potential bio-
marker for lymph node metastasis in cervical cancer,
which may help to identify patients at high risk and es-
tablish a rationale for selecting appropriate therapeutic
strategies.
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